tradingkey.logo

Evolus Inc

EOLS
6.560USD
-0.620-8.64%
Cierre 11/07, 16:00ETCotizaciones retrasadas 15 min
424.87MCap. mercado
PérdidaP/E TTM

Más Datos de Evolus Inc Compañía

Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology in regulatory development. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins, and injectable dermal fillers.

Información de Evolus Inc

Símbolo de cotizaciónEOLS
Nombre de la empresaEvolus Inc
Fecha de salida a bolsaFeb 08, 2018
Director ejecutivoMr. David Moatazedi
Número de empleados332
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 08
Dirección520 Newport Center Dr Ste 1200
CiudadNEWPORT BEACH
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal92660-7022
Teléfono19492844555
Sitio Webhttps://www.evolus.com/
Símbolo de cotizaciónEOLS
Fecha de salida a bolsaFeb 08, 2018
Director ejecutivoMr. David Moatazedi

Ejecutivos de Evolus Inc

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Vikram Malik
Mr. Vikram Malik
Independent Chairman of the Board
Independent Chairman of the Board
265.91K
+9.47%
Ms. Tatjana Mitchell
Ms. Tatjana Mitchell
Chief Financial Officer
Chief Financial Officer
104.60K
--
Mrs. Brady Stewart
Mrs. Brady Stewart
Independent Director
Independent Director
81.27K
+58.52%
Mr. David N. Gill
Mr. David N. Gill
Independent Director
Independent Director
33.96K
-14.80%
Ms. Karah Parschauer, J.D.
Ms. Karah Parschauer, J.D.
Independent Director
Independent Director
--
--
Mr. Albert G. White, III
Mr. Albert G. White, III
Independent Director
Independent Director
--
--
Mr. Nareg Sagherian
Mr. Nareg Sagherian
Investor Relations
Investor Relations
--
--
Dr. Rui L. Avelar, M.D.
Dr. Rui L. Avelar, M.D.
Chief Medical Officer, Head - Research and Development
Chief Medical Officer, Head - Research and Development
--
--
Mr. David Moatazedi
Mr. David Moatazedi
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
-100.00%
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Vikram Malik
Mr. Vikram Malik
Independent Chairman of the Board
Independent Chairman of the Board
265.91K
+9.47%
Ms. Tatjana Mitchell
Ms. Tatjana Mitchell
Chief Financial Officer
Chief Financial Officer
104.60K
--
Mrs. Brady Stewart
Mrs. Brady Stewart
Independent Director
Independent Director
81.27K
+58.52%
Mr. David N. Gill
Mr. David N. Gill
Independent Director
Independent Director
33.96K
-14.80%
Ms. Karah Parschauer, J.D.
Ms. Karah Parschauer, J.D.
Independent Director
Independent Director
--
--
Mr. Albert G. White, III
Mr. Albert G. White, III
Independent Director
Independent Director
--
--

Desglose de ingresos

Sin datos
Sin datos
Por negocio
Por región
Sin datos

Estadísticas de accionistas

Actualizado: sáb., 23 de ago
Actualizado: sáb., 23 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Tang Capital Management, LLC
7.71%
Nantahala Capital Management, LLC
6.48%
Lynch (Timothy Patrick)
6.32%
BlackRock Institutional Trust Company, N.A.
5.63%
The Vanguard Group, Inc.
5.27%
Otro
68.59%
Accionistas
Accionistas
Proporción
Tang Capital Management, LLC
7.71%
Nantahala Capital Management, LLC
6.48%
Lynch (Timothy Patrick)
6.32%
BlackRock Institutional Trust Company, N.A.
5.63%
The Vanguard Group, Inc.
5.27%
Otro
68.59%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
38.18%
Investment Advisor
25.41%
Investment Advisor/Hedge Fund
15.74%
Individual Investor
8.47%
Private Equity
7.59%
Corporation
3.30%
Research Firm
1.99%
Bank and Trust
0.56%
Pension Fund
0.56%

Participación institucional

Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
365
58.53M
90.34%
+162.34K
2025Q2
362
58.85M
90.98%
-2.31M
2025Q1
367
61.71M
95.75%
-6.80M
2024Q4
349
59.00M
93.18%
-8.33M
2024Q3
345
58.57M
92.95%
-9.62M
2024Q2
337
59.72M
95.46%
-6.66M
2024Q1
324
57.99M
95.42%
-6.59M
2023Q4
309
53.87M
93.36%
-7.99M
2023Q3
309
51.63M
90.65%
-8.83M
2023Q2
309
53.08M
93.27%
-5.08M
Ver más

Actividad de los accionistas

Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Tang Capital Management, LLC
5.00M
7.73%
--
--
Jun 30, 2025
Nantahala Capital Management, LLC
4.20M
6.49%
+546.58K
+14.97%
Jun 30, 2025
Lynch (Timothy Patrick)
4.09M
6.33%
+4.09M
--
Aug 11, 2025
BlackRock Institutional Trust Company, N.A.
3.65M
5.64%
-175.30K
-4.58%
Jun 30, 2025
The Vanguard Group, Inc.
3.31M
5.11%
+84.18K
+2.61%
Jun 30, 2025
Caligan Partners, LP
3.34M
5.17%
+610.82K
+22.36%
Jun 30, 2025
Perceptive Advisors LLC
2.47M
3.83%
-1.65M
-40.06%
Jun 30, 2025
Frazier Life Sciences Management, L.P.
2.44M
3.77%
+2.44M
--
Jun 30, 2025
Medy Tox Inc
2.14M
3.3%
-1.24M
-36.82%
Dec 31, 2024
Soleus Capital Management, L.P.
2.12M
3.28%
+1.04M
+96.36%
Jun 30, 2025
Ver más

ETFs relacionados

Actualizado: jue., 6 de nov
Actualizado: jue., 6 de nov
Nombre
Proporción
SPDR S&P Pharmaceuticals ETF
0.85%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
0.64%
iShares U.S. Pharmaceuticals ETF
0.15%
iShares Micro-Cap ETF
0.07%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.06%
ProShares Ultra Nasdaq Biotechnology
0.04%
Invesco Nasdaq Biotechnology ETF
0.04%
iShares Russell 2000 Growth ETF
0.02%
Schwab U.S. Small-Cap ETF
0.01%
Proshares Ultra Russell 2000
0.01%
Ver más
SPDR S&P Pharmaceuticals ETF
Proporción0.85%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proporción0.64%
iShares U.S. Pharmaceuticals ETF
Proporción0.15%
iShares Micro-Cap ETF
Proporción0.07%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proporción0.06%
ProShares Ultra Nasdaq Biotechnology
Proporción0.04%
Invesco Nasdaq Biotechnology ETF
Proporción0.04%
iShares Russell 2000 Growth ETF
Proporción0.02%
Schwab U.S. Small-Cap ETF
Proporción0.01%
Proshares Ultra Russell 2000
Proporción0.01%

Dividendos

Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos

División de acciones

Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
KeyAI